Dupixent® (Dupilumab) Approved in the European Union as the First-Ever Targeted Therapy for Patients With Copd
Dupixent®(Dupilumab)已在歐盟獲批,成爲首個針對慢性阻塞性肺病患者的靶向治療。
Dupixent® (Dupilumab) Approved in the European Union as the First-Ever Targeted Therapy for Patients With Copd
Dupixent®(Dupilumab)已在歐盟獲批,成爲首個針對慢性阻塞性肺病患者的靶向治療。
譯文內容由第三人軟體翻譯。